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Abstract. 
 
We have previously reported that a defect in 
Myo2p, a myosin in budding yeast (
 
Saccharomyces cere-
visiae
 
), can be partially corrected by overexpression of 
Smy1p, which is by sequence a kinesin-related protein 
(Lillie, S.H., and S.S. Brown. 1992. 
 
Nature
 
. 356:358–
361). Such a functional link between putative actin- and 
microtubule-based motors is surprising, so here we 
have tested the prediction that Smy1p indeed acts as a 
microtubule-based motor. Unexpectedly, we found that 
abolition of microtubules by nocodazole does not inter-
fere with the ability of Smy1p to correct the mutant 
Myo2p defect, nor does it interfere with the ability of 
Smy1p to localize properly. In addition, other perturba-
tions of microtubules, such as treatment with benomyl 
or introduction of tubulin mutations, do not exacerbate 
the Myo2p defect. Furthermore, a mutation in 
 
SMY1
 
 
strongly predicted to destroy motor activity does not 
destroy Smy1p function. We have also observed a ge-
netic interaction between 
 
SMY1
 
 and two of the late 
 
SEC
 
 mutations, 
 
sec2
 
 and 
 
sec4.
 
 This indicates that 
Smy1p can play a role even when Myo2p is wild type, 
and that Smy1p acts at a specific step of the late secre-
tory pathway. We conclude that Smy1p does not act as 
a microtubule-based motor to localize properly or to 
compensate for defective Myo2p, but that it must in-
stead act in some novel way.
 
I
 
n 
 
Saccharomyces cerevisiae
 
, virtually all growth occurs
in the bud rather than in the mother cell. 
 
MYO2
 
 en-
codes an unconventional class V myosin that has been
implicated in this polarized growth by studies of the tem-
perature-sensitive 
 
myo2-66
 
 mutant. This mutant fails to
target growth to the bud at restrictive temperature, result-
ing in abnormally large mother cells (see Fig. 1 
 
a
 
; Johnston
et al., 1991). Because vesicles were observed to accumu-
late in the mutant, Johnston et al. (1991) proposed that
Myo2p targeted growth by delivering secretory vesicles to
the bud. The recent finding that in chick brain a class V
myosin is associated with synaptic vesicles (Prekeris and
Terrian, 1997) would seem to suggest that other class V
myosins might have similar functions. The evidence that
Myo2p is a secretory vesicle motor, however, is far from
conclusive (Liu and Bretscher, 1992; Govindan et al.,
1995), and there are other ways that Myo2p might target
growth. For example, it might deliver elements of the ER
or Golgi apparatus, which are found in proximity to the
bud at a very early stage of bud growth (Preuss et al.,
1992). Another possibility is that Myo2p might reside at
the bud tip as part of a complex that anchors the actin cy-
toskeleton or cell wall–synthesizing machinery.
Smy1p, when overexpressed, can partially compensate
for defects in the 
 
myo2
 
 mutant, overcoming lethality and
restoring polarized growth at restrictive temperature (Lillie
and Brown, 1992, 1994). Furthermore, a 
 
myo2 smy1
 
D
 
(SMY1 deletion) double mutant is dead at permissive tem-
perature, despite the fact that each single mutant appears
wild type under the same conditions (Lillie and Brown,
1992). This demonstrates that Smy1p is not simply provid-
ing some “spillover function” when overexpressed, but
also that it is essential in a 
 
myo2
 
 mutant background. An
even stronger indication of the functional significance of
the interaction is that Myo2p and Smy1p colocalize, and
that their localizations respond identically to several cell
perturbations (Lillie and Brown, 1994). Furthermore, over-
expression of Smy1p not only restores Myo2p mutant lo-
calization, but it also enhances the localization of wild-type
Myo2p.
What is particularly surprising about the close relation-
ship between Myo2p and Smy1p is that although both are
putative motor proteins, they are predicted to interact
with different cytoskeletal filaments. Myo2p is expected to
interact with actin filaments, which have also been impli-
cated in polarized growth by their changing localization
during the cell cycle (Adams and Pringle, 1984; Kilmartin
and Adams, 1984) and by studies of actin mutants (Novick
and Botstein, 1985). Smy1p, on the other hand, is by se-
quence a kinesin-related protein (Lillie and Brown, 1992)
and is thus expected to interact with microtubules. Some
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time ago, it was believed that cytoplasmic microtubules
would be required for bud growth, given their location;
they emanate from the spindle pole body at the nuclear
membrane and extend into the growing bud. Genetic and
nocodazole studies have clearly shown, however, that mi-
crotubules are not required for bud growth, but instead,
that they are required for nuclear migration and mitosis
(Jacobs et al., 1988; Huffaker et al., 1988). Although mi-
crotubules together with Smy1p might act as a backup sys-
tem that is needed for bud growth only when Myo2p is de-
fective, such functional overlap would nonetheless be
surprising.
Another consideration is the relative divergence of Smy1p
compared to other members of the kinesin superfamily
(Lillie and Brown, 1992; Goldstein, 1993), which raises the
question of whether it is truly a microtubule-based motor.
The three-dimensional structures of the motor domains of
both myosin and kinesin have been determined (Rayment
et al., 1993; Kull et al., 1996). Whereas these two families
of motors show a remarkable similarity in their core struc-
tures, the insertions that confer microtubule vs. myosin
binding are quite different (Kull et al., 1996; Woehlke et
al., 1997). Smy1p has some sequence divergence in regions
corresponding to the microtubule-binding regions, but not
enough to judge whether it is likely to bind microtubules.
For example, in the loop determined by mutagenesis stud-
ies to be the most critical for microtubule binding (Woehlke
et al., 1997), Smy1p retains an important arginine (corre-
sponding to R278) but has changes in other conserved res-
idues. On the other hand, costal2, another divergent kine-
sin-related protein, does not retain this arginine but does
bind microtubules (Sisson et al., 1997). Smy1p also has
changes that could affect other aspects of motor function.
It is divergent at two otherwise extremely conserved posi-
tions (corresponding to E250 and E311 in Woehlke et al.,
1997) where mutations affect the ability of kinesin to be
activated by microtubule binding. Other sites of diver-
gence might affect interactions with nucleotide (N-1 through
N-4 in Sablin et al., 1996); costal2 shows even more diver-
gence in these regions (Sisson et al., 1997). In summary,
sequence comparison does not allow us to predict whether
Smy1p can bind microtubules, but it does raise the possi-
bility that Smy1p, like costal2, may be a poor or even non-
functional motor.
In this report, we have looked for functional evidence to
determine whether Smy1p interacts with microtubules.
Our results show that Smy1p does not require microtu-
bules to localize properly or to compensate for mutant
Myo2p defects.
 
Materials and Methods
 
Yeast Strains and Media
 
All yeast strains used are listed in Table I. The liquid media used were rich
medium YM-P (yeast medium-Pringle; Lillie and Pringle, 1980) or yeast
extract/peptone/dextroxe medium (YPD)
 
1
 
 (Sherman et al., 1986) and syn-
thetic complete medium lacking the appropriate supplement to select for
plasmid (Sherman et al., 1986). Solid media were made by adding 1.5%
agar to YPD or synthetic complete medium. For all media, glucose was
autoclaved separately and added to 2%, except that in preparation for
sporulation, cultures were often grown in 0.5% glucose instead. Cultures
were grown at room temperature (20–23
 
8
 
C) unless otherwise specified.
 
DNA Manipulations and Genetic Techniques
 
Standard procedures were used for DNA manipulations and 
 
Escherichia
coli
 
 transformation (Sambrook et al., 1989) and for yeast transformation
and genetic manipulations (Sherman et al., 1986).
To alter amino acid 119 of Smy1p from Gly to Glu, a missense mutation
(
 
smy1-3
 
) was introduced by site-directed mutagenesis (using the double-
primer method; Sambrook et al., 1989) of a single-stranded template, us-
ing the following mutagenic primer: GTTTCAGCGAAAAGTCCTA.
The mutation was confirmed by sequencing and then shuttled as a KpnI-
XbaI fragment to KpnI-XbaI-cut pBR-SMY1 [pBR322 (Sambrook et al.,
1989) with a 
 
z
 
4.5-kb EcoRV 
 
SMY1
 
-containing insert]. The 
 
z
 
3.3-kb
HpaI-EcoRV 
 
smy1-3
 
–containing fragment from this plasmid was inserted
into SmaI-digested YEp352 (Hill et al., 1986) to give YEpsmy1-52.
YEpSMY1-52 was constructed by shuttling the corresponding wild-type
 
SMY1
 
 segment from pBR-SMY1 to YEp352.
 
Nocodazole Treatment and Immunofluorescence
 
Nocodazole (Sigma Chemical Co., St. Louis, MO) was added to exponen-
tially growing cultures (1–2 
 
3
 
 10
 
6
 
 cells/ml) as described by Jacobs et al.
(1988), except that stocks were stored in aliquots at 
 
2
 
80
 
8
 
C, and these
were warmed briefly to 50
 
8
 
C immediately before use to ensure complete
solubilization. At each time point, samples were fixed, and an aliquot was
processed for Smy1p, Myo2p, or microtubule staining by indirect immuno-
fluorescence, as described by Lillie and Brown (1994). (Formaldehyde was
added directly to shaking cultures to minimize loss of labile structures.)
Samples were examined using a range of antitubulin concentrations to op-
timize conditions for detection of microtubules.
Cells eventually escape the effects of nocodazole (Jacobs et al., 1988),
and this occurs more rapidly when a greater than optimum concentration
is used (see Fig. 2, compare 
 
a
 
 and 
 
d
 
). Therefore, for each strain and set of
experimental conditions, we carried out pilot experiments using a series of
nocodazole concentrations to find the narrow window where the drug had
its greatest effect. The length of the nocodazole block is also dependent
on a number of other factors. Haploids are more resistant to the drug than
diploids (our observations and Stearns, T., personal communication), and
nocodazole is more effective in rich medium than in selective medium.
Furthermore, escape is enhanced at a higher temperature. We took ad-
vantage of these findings to maximize the length of the nocodazole block.
Diploids were used in nocodazole experiments, cells were shifted to rich
medium if they had been grown in selective medium, and the experiment
in Fig. 2 was carried out without elevating the temperature. In addition,
for the experiment in Fig. 1, we used diploids heterozygous for the 
 
tub1-1
 
allele. This 
 
a
 
-tubulin mutation increases sensitivity to nocodazole, even
when heterozygous (our observations and Stearns, T., personal communi-
cation), which is useful, because the homozygous but not the heterozygous
 
tub1
 
 mutant shows an elevated number of large-budded cells even at per-
missive temperature in the absence of nocodazole. We confirmed that
 
tub1
 
 does not qualitatively alter the results in experiments using other
 
myo2
 
 strains that were wild type for 
 
TUB1
 
 (not shown).
 
Results
 
Smy1p Does Not Require Microtubules to Compensate 
for Myo2p Defects
 
By sequence, Smy1p is clearly a kinesin-related protein
(Lillie and Brown, 1992), but its divergence (see Introduc-
tion) raised the question of whether it functioned as ex-
pected. To ask whether microtubules were required for
Smy1p function, we tested the effects of the microtubule-
depolymerizing drug nocodazole on the best characterized
function of Smy1p, its ability to compensate for 
 
myo2
 
 mutant
defects. Nocodazole causes arrest of wild-type cells at the
large-budded stage of the cell cycle (Fig. 1 
 
a
 
) because mi-
tosis, but not bud growth, is blocked (Jacobs et al., 1988).
 
1. 
 
Abbreviations used in this paper
 
: YM-P, yeast medium-Pringle; YPD,
yeast extract/peptone/dextrose medium. 
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Table I. Yeast Strains Used in This Study
 
Strain Relevant genotype* Source
 
‡
 
ABY167
 
MAT
 
a
 
, 
 
tpm1
 
D
 
::LEU2, ura3, leu2, his3, ade2
 
A. Bretscher (Cornell University, Ithaca, NY)
APY4
 
D
 
D6
 
MAT
 
a
 
, 
 
smy1
 
D
 
-1::URA3, ura3, leu2, trp1, ade2, his6
 
BDY4
 
MAT
 
a
 
, 
 
tpm2
 
D
 
::HIS3, ura3, leu2, his3, trp1, ade2
 
A. Bretscher
DBY1993
 
MAT
 
a
 
, act1-2, ura3
 
D. Botstein (Stanford University, Stanford, CA)
DBY1999
 
MAT
 
a
 
, “act1-3”
 
 (
 
5
 
act1-1
 
), 
 
ura3
 
D. Botstein
CUY51
 
MAT
 
a
 
, tub2-104, ura3, his4
 
T. Huffaker (Cornell University)
CUY72
 
MAT
 
a
 
, tub2-402, ura3, his4, lys2
 
T. Huffaker
CUY75
 
MAT
 
a
 
, tub2-403, ura3, his4, lys2
 
T. Huffaker
CUY80
 
MAT
 
a
 
, tub2-404, ura3, his4, lys2
 
T. Huffaker
CUY83
 
MAT
 
a
 
, tub2-405, ura3, his4, lys2
 
T. Huffaker
DPY3
 
MAT
 
a
 
, tub2-406, ura3, his4
 
T. Huffaker
MAY545
 
MAT
 
a
 
, tub1-1, ura3, leu2 his3, lys2
 
M.A. Hoyt (Johns Hopkins University, Baltimore, MD)
MAY755
 
MAT
 
a
 
, tub3::TRP1, ura3, leu2, trp1, his3
 
M.A. Hoyt
MAY2065
 
MAT
 
a
 
, cin8::URA3, ura3, leu2, his3, lys2, ade2
 
M.A. Hoyt
MS524
 
MAT
 
a
 
, kar3-101::LEU2, ura3, leu2, ade2
 
M. Rose (Princeton University, Princeton, NJ)
MS2305
 
MAT
 
a
 
, kip1-2::URA3, ura3, leu2, trp1
 
M. Rose
MS2309
 
MAT
 
a
 
, kip2
 
D
 
1::URA3, ura3, leu2, his3, ade2
 
M. Rose
myo3
 
D
 
-4Ca
 
§
 
MAT
 
a
 
, myo3
 
D
 
::HIS3, ura3, leu2, trp1, his3
 
NY3
 
MAT
 
a
 
, sec1-1, ura3
 
P. Novick (Yale University, New Haven, CT)
NY17
 
MAT
 
a
 
, sec6-4, ura3
 
P. Novick
NY57
 
MAT
 
a
 
, sec9-4, ura3
 
P. Novick
NY61
 
MAT
 
a
 
, sec10-2, ura3
 
P. Novick
NY64
 
MAT
 
a
 
, sec15-1, ura3
 
P. Novick
NY130
 
MAT
 
a
 
, sec2-41, ura3
 
P. Novick
NY402
 
MAT
 
a
 
, sec5-24, ura3
 
P. Novick
NY405
 
MAT
 
a
 
, sec4-8, ura3
 
P. Novick
NY410
 
MAT
 
a
 
, sec8-9, ura3
 
P. Novick
NY425
 
MAT
 
a
 
, sec22-3, ura3
 
S. Ferro-Novick (Yale University)
NY427
 
MAT
 
a
 
, sec12-4, ura3, leu2, trp1, his4
 
S. Ferro-Novick
NY432
 
MAT
 
a
 
, sec18-1, ura3
 
P. Novick
NY760
 
MAT
 
a
 
, sec7-1, ura3
 
P. Novick
RH268-1C
 
MAT
 
a
 
, end4-1, ura3, leu2, his4, bar1
 
H. Riezman (University of Basel, Basel, Switzerland)
RH299-1C
 
MAT
 
a
 
, end4
 
D
 
::LEU2, ura3, leu2, lys2, his4, bar1
 
H. Riezman
RH1995
 
MAT
 
a
 
, end3
 
D
 
::URA3, ura3, leu2, his4, bar1
 
H. Riezman
SBY3
 
MAT
 
a
 
, myo1
 
D
 
::LEU2, ura3, leu2, his4
SBY4 MATa, myo1D::LEU2, ura3, leu2, his4, trp1
SLY34 MATa, myo2-66, ura3, leu2 (Lillie and Brown, 1994)
SLY55 MATa, smy1D-2::LEU2, ura3, leu2, his4
SLY57 MATa, smy1D:-2:LEU2, ura3, leu2, trp1, his4
SLY63 MATa, myo2-66, ura3, leu2, trp1, his6
SLY81 MATa, myo2-66, leu2
SLY82 MATa, myo2-66, leu2, his3
SLY83 MATa, myo2-66, leu2, his3
SLY100 MATa, smy1D-1::URA3, ura3, leu2, trp1, his4
SLY102 MATa, smy1D-1::URA3, ura3, leu2, trp1
SLY103 MATa/a, myo2-66/MYO2 SMY1/smy1D-2::LEU2 ura3/ura3 leu2/leu2 his4/HIS4
SLY109 MATa, smy1D-2::LEU2, ura3, leu2, his3, ade2, ade3
SLY111 MATa, smy1D-2::LEU2, ura3, leu2, his3, ade2, ade3
SLY163i MATa, cmd1-3, ura3, leu2, his3
SLY164i MATa, cmd1-3, leu2, his3
SLY165i MATa, cmd1-1, ura3, leu2, his3
SLY166i MATa, cmd1-1, leu2, his3
SLY191¶ MATa, myo2-66, smy1D-2::LEU2, ura3, leu2, his4, [YEpsmy1-52]
SLY192¶ MATa, myo2-66, smy1D-2::LEU2, ura3, leu2, [YEpsmy1-52]
SLY194¶ MATa, myo2-66, smy1D-2::LEU2, ura3, leu2, [YEpSMY1-52]
SLY195¶ MATa, myo2-66, smy1D-2::LEU2, ura3, leu2, his4, [YEpSMY1-52]
SLY248 MATa/a, ura3/ura3
SLY250 MATa/a, myo2-66/myo2-66, ura3/ura3
SLY251 MATa/a, myo2-66/myo2-66, ura3/ura3
SLY254 MATa, myo2-66, ura3
SLY334** MATa/a, myo2-66/myo2-66, tub1-1/TUB1, ura3/ura3 leu2/LEU2, his3/HIS3
314D5 MATa/a, cdc4-1/cdc4-1, ura1/ura1, tyr1/tyr1, ade1/ade1, ade2/ade2 L. Hartwell (University of Washington, Seattle, WA)
*Some strains may carry additional mutations; most or all are S288C derivatives and therefore gal2.
‡This study, except as noted.
§Made by crossing HA1C (H. Goodson and J. Spudich) into our strain background.
iMade by crossing JGY41 or JGY44-2A (T. Davis) into our strain background.
¶Segregants obtained from SLY103 carrying the indicated plasmids.
**tub1-1 allele originally from M.A. Hoyt.The Journal of Cell Biology, Volume 140, 1998 876
The  myo2 mutation, on the other hand, interferes with
bud growth so that mutant cells at restrictive temperature
are not able to reach the large-budded stage. Because this
defective bud growth can be overcome by overexpression
of Smy1p, we asked whether myo2-mutant cells carrying
multicopy SMY1 could reach large-budded arrest when
treated with nocodazole, as a test of whether Smy1p could
restore bud growth in the absence of microtubules. myo2
mutant cells containing multicopy SMY1 or vector alone
were shifted to restrictive temperature, and nocodazole
(or the DMSO carrier only) was added 1 h later (indicated
by the arrow in Fig. 1 b). After about a half-hour lag, cells
with multicopy SMY1 rapidly accumulated at the nocoda-
zole block, which was detected as an increase in the per-
centage of large-budded cells (Fig. 1 b, closed circles),
whereas mock-treated cells (open circles) continued to
pass through the cell cycle and maintained an approxi-
mately constant fraction of large-budded cells. In the con-
trol culture (myo2 mutant cells with vector alone), there
was very little bud growth regardless of whether nocoda-
zole was present (consistent with previous observations;
Johnston et al., 1991; Lillie and Brown, 1992, 1994). Ap-
proximately 15% of these control myo2 mutant cells pro-
duced visible buds at restrictive temperature (inferred
from the reduction in the unbudded population; Fig. 1 c,
triangles), but none of those buds grew enough to reach
the large-budded stage (Fig. 1 b, triangles). Cytoplasmic
microtubules were no longer detectable 30 min after no-
codazole addition, as assessed by immunofluorescence mi-
croscopy. We conclude from this experiment that Smy1p
can restore bud growth in the absence of microtubules;
a model in which Smy1p compensates by carrying the
Myo2p cargo along microtubules is ruled out. But what if
Smy1p needed microtubules only to reach its location
early in the cell cycle, and once localized, could compen-
sate without further microtubule involvement? Such a
possibility is not ruled out by the experiment above, but is
ruled out by the localization experiments described below.
The experiment above has a couple of complications,
which, however, do not abrogate our conclusion. The first
is that the shift to restrictive temperature causes a tran-
Figure 1. SMY1-dependent bud growth in the myo2 mutant at re-
strictive temperature does not require microtubules. (a) Nocoda-
zole causes arrest at the large-budded stage of the cell cycle be-
cause mitosis but not bud growth is blocked (Jacobs et al., 1988),
whereas the myo2 mutation interferes with bud growth giving rise
to abnormally large mother cells (Johnston et al., 1991). Counts
were made of large-budded (b) and unbudded (c) cells in cultures
of the myo2 mutant (strain SLY334) carrying multicopy SMY1
(YEpSMY1-52; circles) or control vector (YEp352; triangles). Cells
growing in selective medium at 258C were shifted to restrictive
temperature (318C) by a fivefold dilution into prewarmed rich
medium (YM-P) (refer to Materials and Methods). 5 mg/ml nocoda-
zole (closed symbols) or carrier (DMSO) alone (open symbols)
was added 1 h later (at the time indicated by the arrow), to allow
time for the myo2 mutation to be “expressed” and for recovery
from the transient effects of the temperature shift (Lillie and
Brown, 1994). At each time point, samples were fixed and an ali-
quot was counted after sonication to disperse clumps of cells. For
each sample, at least 200 cells were scored as unbudded, small
budded, or large budded (cells whose buds were more than three
quarters the size of the mother cell). A second aliquot was pro-
cessed for microtubule staining. In nocodazole-treated cells, all
detectable cytoplasmic microtubules had disappeared by 30 min
after nocodazole addition although putative spindle pole bodies
persisted in many cells and short spindles persisted in an occa-
sional cell. At 21⁄2 h, cytoplasmic microtubules began to reappear
in some cells, concomitant with an increase in spindle pole body
staining. In mock-treated (DMSO carrier alone) cultures, cyto-
plasmic microtubules (and spindle pole bodies) were detectable
in virtually all cells throughout the experiment, while spindles
were present in a fraction of cells.Lillie and Brown Smy1p Does Not Require Microtubules 877
sient increase in the fraction of unbudded cells, peaking at
z1 h (i.e., at 0 h in Fig. 1 c for all four cultures). This has
been observed previously with wild-type cells (Johnston
and Singer, 1980; Plesset et al., 1987), and it is temporally
correlated with transient disorganization of the actin cy-
toskeleton (Lillie and Brown, 1994). The cultures did not
return to the initial percentage of unbudded cells seen at
room temperature, but they instead reached a new, higher
plateau after temperature shift (compare open symbols at
21 h and .2 h in Fig. 1 c). The second complication is that
yeast eventually escapes the effects of nocodazole (Jacobs
et al., 1988). We used a number of strategies to maximize
the length of the nocodazole block (refer to Materials and
Methods), but were only able to prolong it long enough to
allow about half the cells to reach the large-budded arrest
point. Microtubule staining began to reappear at 2 1/2 h of
nocodazole treatment in a small fraction of the cells. Con-
comitant with the reappearance of microtubules, the pro-
portion of large-budded cells began to decline (Fig. 1 b,
closed circles) as the proportion of unbudded cells began
to increase (Fig. 1 c, closed circles), an indication that cells
were indeed resuming mitosis.
The most effective way we found to prolong the nocoda-
zole block was to lower the temperature. Therefore, to
confirm and extend the results obtained at restrictive tem-
perature, we performed an experiment at room tempera-
ture. A change in strains and protocol from that of Fig. 1
was necessitated by the fact that the myo2 mutant does not
require multicopy SMY1 at room [permissive] tempera-
ture. Instead, we compared the effects of nocodazole on
closely matched homozygous myo2 and wild-type diploids
(made by mating sister segregants obtained after several
backcrosses). Since the myo2 smy1D double mutant is invi-
able (Lillie and Brown, 1992), we infer that nocodazole
should have an effect on the rate of bud growth if microtu-
bules were required for the compensating effect of Smy1p
in the myo2 mutant at nominally permissive temperature.
In this experiment, cytoplasmic microtubules were no
longer detectable by 30 min after nocodazole addition and
started to reappear only at 63⁄4 h. Most (see below) myo2-
mutant cells and virtually all wild-type cells were able to
reach large-budded arrest by 21⁄2 h with approximately the
same kinetics (Fig. 2 a). No additional increase in the frac-
tion of large-budded cells was seen in the next 4 h. Fur-
thermore, when either a lower (not shown) or higher (Fig.
2 d) dose of nocodazole was used, both of which imposed a
shorter block, the myo2-mutant strains once again dis-
played similar rates of bud growth and escape from no-
codazole as the wild-type strains did.
We conclude that the room temperature experiment
does indeed confirm the results obtained in the experi-
ment performed at restrictive temperature in that a large
fraction of mutant cells behave like wild-type cells in re-
sponse to nocodazole. We were, however, puzzled by the
Figure 2. The myo2 mutant, which requires Smy1p at permissive tempera-
ture, does not need microtubules for bud growth. Wild-type (SLY248; trian-
gles) or myo2-mutant (the average of counts using SLY250 and SLY251; cir-
cles) cells growing exponentially in rich medium (YM-P) at 228 were treated
at 0 h with 10 (a–c) or 15 (d) mg/ml nocodazole, and counts were made of un-
budded (b), small-budded (c), and large-budded (a and d) cells. Results of
two separate experiments are shown, indicated by open and closed symbols.
At each time point, samples were fixed and counted or were stained for micro-
tubules, as described in Fig. 1. Addition of carrier DMSO alone had no effect
on the proportions of unbudded versus budded cells (data not shown). In
cells treated with 10 mg/ml nocodazole, all detectable cytoplasmic microtu-
bules had disappeared by 30 min and started to reappear only at 63⁄4 h. (Spin-
dles persisted for some time in 1–3% of the cells, and spindle pole bodies re-
mained detectable in many cells throughout the experiment.) In cells treated
with a lower (5 mg/ml, data not shown) or higher (15 mg/ml [d]) nocodazole
dose, cytoplasmic microtubules reappeared at z3 3/4 h. In mock-treated cul-
tures (DMSO alone), virtually all cells had detectable cytoplasmic microtu-
bules at all times.The Journal of Cell Biology, Volume 140, 1998 878
difference in plateau values for wild-type vs. mutant cells.
The mutant cells that failed to reach the large-budded
stage did not appear to arrest at a specific stage because
both unbudded and small-budded cells remained (Fig. 2, b
and c). It seemed unlikely that mutant cells were more sus-
ceptible to some poisoning effect of nocodazole because
the same fraction of myo2 cells failed to reach the large-
budded stage using a range of nocodazole concentrations
(from 5 to 15 mg/ml; compare Fig. 2, a and d). We there-
fore examined cells that had not been treated with no-
codazole for their ability to grow. The same strains that we
used in Fig. 2 were plated as single cells at room tempera-
ture (in the absence of nocodazole) and examined micro-
scopically at various times thereafter. Essentially all of the
wild-type control cells and most of the mutant cells were
able to grow buds and divide several times during the
timecourse of the experiment (Fig. 3). However, 10–20%
of the myo2-mutant cells never divided; instead, they re-
mained as single cells that were either unbudded or had
buds of various sizes. These nondividing myo2 cells were
not dead by the criterion of dye exclusion (not shown). Al-
though we cannot explain this behavior, it could account
for the difference in plateau values between wild-type and
myo2-mutant cells in Fig. 2.
In addition to nocodazole treatment, we tried other ap-
proaches predicted to perturb microtubules. We did not
observe any genetic interactions between myo2 and any of
several a- or b-tubulin mutations (a total of eight alleles
from the three tub genes were tested; Table II) despite the
fact that myo2 is synthetically lethal with smy1D (Lillie
and Brown, 1992). Furthermore, we found that myo2-
mutant strains were not more sensitive than related wild-
type strains to benomyl, another drug that acts on micro-
tubules (Stearns and Botstein, 1988). Tetrads of four
well-backcrossed  myo2/MYO2 diploids were dissected, and
segregants were replica-pronged onto YPD plates contain-
ing 0, 10, 15, 20, and 25 mg/ml benomyl (Thomas et al.,
1985) at 228C. For one of the crosses, cells were spread on
sectors of the same plates to better assess relative growth.
No consistent differences between myo2 and wild-type
segregants were seen. Both grew well at 10 mg/ml of
benomyl, less well at 15 mg/ml, and very little growth was
seen at 20 or 25 mg/ml. These results are consistent with
the hypothesis that Smy1p does not require microtubules
to compensate for the Myo2p defect.
Smy1p Does Not Require Microtubules for Localization
It seemed likely that Smy1p must localize properly to com-
pensate for the Myo2p defect, given the apparent colocal-
ization of these proteins, the loss of localization of both
proteins in the myo2 mutant at restrictive temperature,
and the restoration of localization of both when Smy1p is
overexpressed (Lillie and Brown, 1994). We therefore
tested whether Smy1p localization was microtubule de-
pendent. Smy1p and Myo2p colocalize as a “cap” at grow-
ing bud tips (Lillie and Brown, 1994), and this localization
can indeed be seen in nocodazole-treated wild-type cells
Figure 3. Some myo2-mutant cells fail to multiply at permissive
temperature. Logarithmically growing myo2 mutant (SLY251;
circles) or wild-type (SLY248; triangles) cells (in YM-P) were
briefly sonicated to disperse clumps and plated as single cells on
YPD at room temperature. At each timepoint, the plates were
examined microscopically to determine what fraction of the cells
had undergone division. Most cells underwent several cell divi-
sions during the time course of the experiment, giving rise to a
microcolony. 200 cells and/or microcolonies per strain were ex-
amined at each time point.
Table II. Synthetic Lethal Relationships*
myo2-66 smy1D
Microtubules
a tubulin (tub1-1, tub3D) 1 ND
b tubulin (tub2)‡ 11
Kinesin-related proteins§ ND 1
Actin (act1-1, act1-2)N D 1
Tropomyosins
tpm1D 2i 1
tpm2D 1i 1
Myosins
myo1D 66
myo2-66 NA 2¶
myo3D 11
myo4D 1** 1**
Calmodulin
cmd1-1 2‡‡ 1
cmd1-3 1‡‡ 1
Late secretory
sec2-41, 4-8 2§§ 2
sec5-24, 8-9, 9-4, 10-2, 15-1 2§§ 1
sec 1-1, 6-4 1§§ 1
Early secretoryii 1§§ 1
Endocytic (end3D, end4D) 11 ¶¶
*1, double mutants were alive; 2, double mutants were dead; 6, live mutants were
obtained, but under some conditions, they grew slowly (or not at all) compared to ei-
ther single mutant. ND, not done; NA, not applicable.
For crosses performed in our laboratory, a temperature permissive for the two parent
single mutants was used throughout. For each cross, 9–35 tetrads were dissected on
YPD. The segregants were replica pronged to selective plates at permissive tempera-
ture and/or YPD plates at appropriate temperatures to infer genotypes, and, in crosses
with live double mutants, to look for synthetic growth defects.
‡tub2-104, -402, -403, -404, -405, -406.
§kar3D, cin8D, kip1D, kip2D.
iPerformed by A. Bretscher laboratory.
¶Lillie and Brown (1992).
**Haarer et al (1994).
‡‡Confirmation of Brockerhoff et al. (1994) in our strain background.
§§Performed by Govindan et al. (1995).
iisec7-1, 12-4, 18-1, 22-3.
¶¶end4-1 instead of end4D was used.Lillie and Brown Smy1p Does Not Require Microtubules 879
and myo2 mutant cells with multicopy SMY1 (not shown).
These cells, however, were not optimal for quantitation of
nocodazole effects. This is because caps are detectable
only in (some) unbudded and small-budded cells (Lillie
and Brown, 1994), classes that are lost from the population
as cells accumulate at the nocodazole block. We circum-
vented this problem by using cdc4 mutant cells at restric-
tive temperature because these cells continue to produce
buds even in the presence of nocodazole (Jacobs et al.,
1988). Strikingly, treating cdc4 cells with nocodazole (as
described in Fig. 4) had absolutely no effect on the fre-
quency of cells with Smy1p (or Myo2p) caps (illustrative
cells shown in Fig. 4, c and d). Counts made 60, 95, and 120
min after nocodazole addition revealed that 59–64% of
the nocodazole-treated cells had Smy1p caps, as compared
to 58–66% of the control cells. The frequencies of Myo2p
caps in control (84–88%) and nocodazole-treated (85–
90%) cells were also indistinguishable. (The frequencies of
Myo2p caps were higher than those of Smy1p caps, pre-
sumably because Smy1p caps are more difficult to stain;
Lillie and Brown, 1994). We confirmed that microtubules
were efficiently abolished in these cells (0% of nocoda-
zole-treated cells had detectable cytoplasmic microtu-
bules, as compared to 94–97% of control cells; illustrated
in Fig. 4, a and b). Thus, Smy1p (and Myo2p) clearly re-
main localized properly without microtubules. We infer
that new Smy1p caps can also form without microtubules
because the cells continue to make new buds. Further-
more, small buds, which almost certainly formed in the ab-
sence of microtubules (see Fig. 6 in Jacobs et al., 1988),
displayed prominent Smy1p caps (see arrow in Fig. 4 d).
To address this point more directly, we used osmotic
shock to eliminate Smy1 caps (see Lillie and Brown, 1994)
in cdc4 cells after microtubules had been abolished by no-
codazole (Fig. 5). We then asked whether caps could re-
form in the absence of microtubules. Control cells that had
not been nocodazole treated lost their caps within 5–10
min after the addition of 0.4 M NaCl, and they recovered
the caps after about a half hour, as expected (Lillie and
Brown, 1994). Nocodazole-treated cells behaved identically
despite the lack of cytoplasmic microtubules throughout
the experiment (compare closed and open circles in Fig. 5).
Thus, it is clear that microtubules are not required for
Smy1p cap formation. This conclusion is relevant to the
bud growth experiments of Figs. 1 and 2 for the following
reason. Smy1p localization is almost surely necessary for
its ability to compensate for the myo2 mutant defect in bud
growth, and we imagine that both formation and mainte-
nance of caps are involved in this process. If only forma-
tion were critical, however, microtubule dependence at this
step would not have shown up in the bud growth experi-
ments, which, for the most part, looked at cells that would
have already formed caps before nocodazole addition. The
fact that Smy1p caps can form in the absence of microtu-
bules removes this reservation about the bud growth ex-
periments, allowing us to state unequivocally that Smy1p
can function without microtubules.
Smy1p May Not Require Motor Activity to Localize or 
Compensate for Myo2p Defects
Our finding that microtubules are not required for Smy1p
function raises the question of whether Smy1p is even a
motor protein. If it is, alteration of the P loop (which binds
to phosphates of ATP) should interfere with Smy1p func-
tion. Meluh and Rose (1990) have found that an alteration
(kar3-1) in the P loop of Kar3p, another yeast kinesin-
related protein, severely compromises its function. There-
fore, we made the same change (smy1-3) in Smy1p, sub-
stituting a Glu for Gly 119 (the second G in the P loop
consensus sequence GX4GKS/T). In contrast to the Kar3p
results, however, this alteration did not interfere with ei-
ther the localization or function of Smy1p. Localization of
mutated Smy1p was carried out in a smy1D background to
avoid staining of wild-type protein, and was indistinguish-
able from that of wild-type Smy1p (data not shown). Fur-
thermore, the mutation did not interfere with the ability of
Figure 4. Smy1p caps are present in cells lacking microtubules.
Immunolocalization of microtubules (a and b) and Smy1p (c and
d) in the multibudded cdc4 mutant (strain 314D5) in the absence
(a and c) or presence (b and d) of 15 mg/ml nocodazole. cdc4/cdc4
diploid cells growing exponentially in YM-P at 248C were shifted
to restrictive temperature (368C) and incubated for 165 min. By
this time, most cells had produced one or two abnormally elon-
gated buds. Nocodazole or carrier DMSO alone was added, and
samples were processed for indirect immunofluorescence micros-
copy at 60, 95, and 120 min. 200 cells/time point were scored for
the presence of Smy1p caps, Myo2p caps, and microtubules; re-
sults were indistinguishable at these three time points (see text
for the ranges). As expected (Jacobs et al., 1988), virtually every
bud contained a prominent bundle of microtubules in the ab-
sence (a) but not the presence (b) of nocodazole. The small dots
seen in b are caused by residual staining of the spindle pole bod-
ies. A subset of the buds contained Smy1p caps (and Myo2p caps;
data not shown) whether (d) or not (c) nocodazole was present.
The arrow in d indicates a (putatively) newly forming bud with a
bright Smy1p cap. Bar, 10 mm.The Journal of Cell Biology, Volume 140, 1998 880
overexpressed Smy1p to overcome the defects of the myo2
mutant. A myo2 mutant strain (SLY34) carrying multi-
copy mutated smy1-3 (YEpsmy1-52) grew as well as the
same strain with wild-type SMY1 (YEpSMY1-52) when
incubated for 4 d on a YPD plate at restrictive tempera-
ture (318C). Subtle differences were sometimes seen; these
may be caused by a slight loss of stability of the mutant
protein at elevated temperature, given the lack of such
ephemeral differences in the experiment below. In con-
trast, no growth was seen with the control plasmid
(Yep352), and all strains grew well on a YPD plate at per-
missive temperature. A reservation is that the myo2 mu-
tant has an endogenous wild-type SMY1 gene in addition
to the overexpressed smy1-3 gene. This could complicate
interpretation if wild-type Smy1p formed functional het-
erodimers with mutant Smy1p (or if there were an unex-
pectedly high rate of gene conversion). Therefore, we used
a second functional test that avoided these complications,
asking whether smy1-3 prevented lethality (Lillie and
Brown, 1992) in a myo2 smy1D double mutant. A het-
erozygous diploid strain (SLY103) carrying each of the
same plasmids as described above was subjected to tetrad
analysis at room temperature. We found that in the vast
majority of tetrads (those that had retained plasmid) all
segregants were viable, except that as expected (Lillie and
Brown, 1992), no live double-mutant segregants were re-
covered from SLY103-carrying control vector. Thus, smy1-3
was able to prevent lethality in the double mutant. Fur-
thermore, the growth rates of double-mutant segregants
carrying wild-type versus mutant SMY1 (strains SLY191,
SLY192, SLY194, and SLY195) incubated at 258C in YPD
were indistinguishable when followed by OD over a pe-
riod of several days (with dilutions to maintain cells in log
phase). Therefore, smy1-3 not only prevented lethality,
but it also allowed cells to grow as well as they did with
SMY1. We conclude from the above experiments that
Smy1p does not need motor activity to localize properly
and to compensate for Myo2p defects.
The above-mentioned kar3-1 mutation causes Kar3p lo-
calization to microtubules to become detectable (Meluh
and Rose, 1990). An attractive interpretation is that the
mutant Kar3p cannot bind ATP well and is therefore
blocked at a step of the ATPase cycle when it is tightly
bound to microtubules (see Hackney, 1994). Therefore,
we looked carefully for mutant Smy1p localization to mi-
crotubules but were unable to detect any. kar3-1 has dom-
inant-negative effects, perhaps because tightly bound mu-
tant protein competes with other microtubule interactions.
We looked for dominant effects with smy1-3 but found no
evidence of this. These findings are consistent with the ev-
idence presented above that Smy1p is not a microtubule-
based motor.
A deletion of amino acids 20–137 (roughly the first third
of the Smy1p “motor” domain including the P loop) abol-
ishes localization and the ability to correct myo2-mutant
defects without reducing the amount of Smy1p present (as
judged by Western analysis; data not shown). This is not
conclusive proof that the motor domain of Smy1p is func-
tionally important because the deletion might cause fold-
ing problems that interfere with other domains. However,
a similar deletion in kinesin did not abolish microtubule
binding (Yang et al., 1989), suggesting that our deletion
may not have such global effects. Assuming that the motor
domain is indeed important, it seems likely that this do-
main is involved in a novel function that Smy1p has ac-
quired.
Synthetic Lethal Relationships
Although they should not be overinterpreted, synthetic in-
teractions (i.e., a more than additive phenotype in a dou-
ble mutant) can provide valuable clues about function. We
have used this approach to ask several questions about
Smy1p. A summary of crosses performed with smy1D (and
myo2) mutants is provided in Table II. First, we looked for
synthetic interactions between smy1D and deletions of
other kinesin-related genes. We reasoned that Smy1p
might indeed be a microtubule-based motor, even though
this activity is not needed for localization or to compen-
sate for the myo2 mutation. If so, the lack of a phenotype
upon SMY1 deletion might indicate redundancy with an-
other kinesin-related protein. However, we found no indi-
cation of a synthetic interaction between smy1D and dele-
tions in KAR3, KIP1, KIP2, or CIN8. The completion of
the yeast genome project has revealed a sixth kinesin-
related gene in yeast, KIP3, which also does not have a
synthetic interaction with smy1D (DeZwaan et al., 1997;
Hoyt, M.A., personal communication). The only other mi-
crotubule-based motor in yeast is dynein, and there is no
synthetic interaction between smy1D and deletion of
Figure 5. Smy1p caps can form in cells lacking microtubules.
cdc4/cdc4 diploid cells (strain 314D5) growing exponentially in
YM-P at 248C were shifted to restrictive temperature (368C) and
incubated for 120 min. By this time, most cells had produced one
or two abnormally elongated buds. 15 mg/ml nocodazole (closed
symbols) or carrier DMSO alone (open symbols) was added, and
after an additional 45 min of incubation, cells were osmotically
shocked (at 0 h) by addition of 0.4 M NaCl (using a 5-M stock).
At each time point, samples were processed for indirect immuno-
fluorescence microscopy, and at least 200 cells were scored for
the presence of cytoplasmic microtubules (triangles) or Smy1p
caps (circles). As observed previously, nocodazole treatment
abolished most cytoplasmic microtubules in ,30 min, while resid-
ual staining of spindle pole bodies remained (Fig. 4 b). We also
noted that the NaCl treatment appeared to retard the loss of nu-
clear microtubules and/or to enhance the formation of an abnor-
mal bar of tubulin in the nucleus (not shown). No change in mi-
crotubule structures was observed upon osmotic shock of control
cells treated with carrier DMSO alone.Lillie and Brown Smy1p Does Not Require Microtubules 881
DYN1 (Cottingham and Hoyt, 1997). Synthetic interac-
tions have implicated all of these microtubule-based mo-
tor proteins in partially overlapping aspects of nuclear mi-
gration and mitosis (Cottingham and Hoyt, 1997; DeZwaan
et al., 1997). SMY1 stands alone in its failure to show any
synthetic interactions.
We have also used this approach to look for further
clues as to the nature of Smy1p’s relationship with Myo2p
and/or other components of the actin cytoskeleton (Table
II). No genetic interactions were seen, except for a subtle
interaction between smy1D and deletion of the gene en-
coding the putative conventional myosin (MYO1). We
also detected a subtle interaction between the MYO1 de-
letion and myo2, and we are investigating these interac-
tions further.
The most informative results we obtained were with mu-
tants defective in the secretory pathway (SEC mutants).
Govindan et al. (1995) have shown that myo2 is syntheti-
cally lethal with mutations in most of the late (but not the
early) SEC genes, suggesting that Myo2p plays a role at a
late stage of secretion. When we tested smy1D against the
same alleles, we found synthetic lethality with two of these
late SEC mutations (sec2 and sec4), but not with the others
nor with the early SEC mutations we tested. These results
are interesting for two reasons. First, they show that
Smy1p plays a role in exocytosis, even when Myo2p is wild
type. In other words, they rule out the possibility that the
only function of Smy1p is to stabilize a mutant Myo2p.
Second, the fact that Smy1p interacts (genetically) with
only a subset of the proteins that interact with Myo2p may
well be a significant clue to the role it plays in secretion.
Discussion
Our working hypothesis at the beginning of this study was
that mutant Myo2p was defective in carrying a cargo along
actin filaments, and that Smy1p might compensate by car-
rying the cargo along microtubules instead. This hypothe-
sis was plausible, given the orientation of both actin fila-
ments and microtubules toward the bud, and given findings
in other systems (Fath et al., 1994; Langford, 1995; Morris
and Hollenbeck, 1995) that a vesicle or organelle can have
both microtubule- and actin-based motors. Our present re-
sults, however, have ruled out this model for Smy1p func-
tion. It is clear from the nocodazole experiments that mi-
crotubules are not required for Smy1p to compensate for
the Myo2p defect, and we have ruled out the possibility
that Smy1p must travel down microtubules to reach the
bud tip. What models remain? We cannot completely rule
out the heretical possibility that Smy1p might travel down
actin filaments, but this notion is not consistent with evi-
dence (discussed below) that Smy1p does not have motor
activity. A second possibility is that Smy1p might interact
with Myo2p to stabilize or otherwise enhance its function.
In this case, Smy1p might be carried along actin filaments
by Myo2p to reach the bud tip. Alternatively, as men-
tioned in the Introduction, Myo2p may not carry a cargo
to the bud tip, but it may instead reside there together with
Smy1p to carry out some function. We have recently ob-
tained evidence that Smy1p and Myo2p do, in fact, inter-
act physically (Beningo, K.A., and S.S. Brown, manuscript
in preparation). This extends our conclusion that there is a
surprising, novel interaction between these proteins, that
does not involve microtubules.
Our conclusion that microtubules are not required for
Smy1p localization and function depends on knowing that
nocodazole has truly abolished all microtubules. Although
we have been careful to stipulate that our results were ob-
tained in the absence of “detectable” microtubules, we are
confident that cytoplasmic microtubules were completely
abolished for several reasons. First, there are not many cy-
toplasmic microtubules in yeast (an average of three per
cell), and cytoplasmic microtubule staining corresponds to
individual microtubules (Carminati and Stearns, 1997).
Second, Jacobs et al. (1988) went to great lengths to dem-
onstrate that nocodazole completely abolishes microtu-
bules in S. cerevisiae. Third, microtubules were functionally
absent; cells were unable to undergo mitosis. Furthermore,
we did not begin to see escape from mitotic arrest until mi-
crotubules began to reappear. Thus, it is thoroughly un-
likely that microtubules persisted that we failed to detect.
The fact that microtubules are not required for Smy1p
to localize or to function led to the prediction that motor
activity would not be required either. Studies of the smy1-3
mutation support this prediction. This mutation has no ap-
parent effects on Smy1p, in contrast to the dramatic effects
of the same mutation (kar3-1; Meluh and Rose, 1990) on
another yeast kinesin-related protein, Kar3p. The loss of
Kar3p function must be caused by a loss of motor activity
because the mutation is in the P loop, a motif that interacts
with the phosphate portion of nucleotide in many NTP-
ases. The mutation alters a glycine that is absolutely con-
served (Saraste et al., 1990) and whose alteration inter-
feres with nucleotide binding and/or inactivates other
NTPases (Clanton et al., 1987; Liu and Summers, 1988;
Logan and Knight, 1993; Shen et al., 1994). Of particular
relevance, given the structural similarity between kinesin
and myosin (Kull et al., 1996), is the effect of this mutation
on Dictyostelium myosin II (Gly184 to Glu); the mutant
myosin no longer binds ATP, and actin binding becomes
ATP insensitive (Ruppel, K., personal communication).
This glycine is critical because of a structural constraint;
any other amino acid in this position destroys the confor-
mation of the P loop (Pai et al., 1990), which is essentially
identical in all NTPases whose three-dimensional struc-
tures have been determined (Kull et al., 1996; Smith and
Rayment, 1996). Thus, this mutation should have affected
the ability of Smy1p to localize or to correct Myo2p de-
fects if motor activity were required. (Note that this would
be the prediction even if Smy1p were to travel along some
novel substrate such as actin.) Our results do not rule out
the possibility that Smy1p could be capable of motor activ-
ity, which is used for some unknown function that has not
been revealed by phenotypic studies. However, our efforts
to observe in vitro motility, ATP binding or hydrolysis,
and cosedimentation with microtubules have all been neg-
ative. Furthermore, the divergence of Smy1p at many oth-
erwise highly conserved positions (see Introduction) also
suggests that it may not be a motor protein.
The synthetic lethal relationships that we have observed
are consistent with earlier evidence that Smy1p is func-
tionally linked with the actin rather than the microtubule
cytoskeleton (Lillie and Brown, 1994). Of particular inter-
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tion and mutations in two of the late SEC genes. The prod-
ucts of the late SEC genes function in the delivery or
fusion of secretory vesicles with the cell membrane, a pro-
cess in which actin (Novick and Botstein, 1985) and
Myo2p (Govindan et al., 1995) have also been implicated.
This synthetic lethality provides new clues about Smy1p
function. The first is that Smy1p must have a function be-
yond that of stabilizing mutant Myo2p, since the synthetic
lethality takes place in cells where MYO2 is wild type.
Smy1p may nonetheless act via Myo2p; we have previ-
ously noted that SMY1 overexpression enhances the local-
ization of even wild-type Myo2p (Lillie and Brown, 1994).
The second clue is that smy1D is synthetically lethal with
mutations in only two of the late SEC genes, whereas
Govindan et al (1995) have shown that myo2 is syntheti-
cally lethal with most late SEC mutations. The two muta-
tions with which smy1D is synthetically lethal, sec2 and
sec4, are not simply the most deleterious of the late SEC
mutations tested (Nair et al., 1990), thus ruling out the
most trivial explanation of these results. Instead, recent
studies indicate that the functions of Sec2p and Sec4p are
intimately associated. Sec4p is a small GTPase (Salminen
and Novick, 1987) that has been postulated to act as a con-
formational switch regulating either the delivery of vesi-
cles or their subsequent capture at the site of fusion. Inter-
estingly, Sec2p has been found to be an exchange factor for
Sec4p (Walch-Solimena et al., 1997). Almost all of the
other late SEC mutations we tested (sec3 [not shown], 5, 6,
8,  10, and 15), which are not synthetically lethal with
smy1D, are components of the “exocyst,” a large complex
of copurifying proteins (TerBush and Novick, 1995; Ter-
Bush et al., 1996). Sec4p continues to localize at the bud
tip in exocyst mutants, indicating that the exocyst is not in-
volved in vesicle localization, but rather, in some subse-
quent event (Walch-Solimena et al., 1997). Sec4p, however,
does not localize in sec2 or myo2-66 mutants (Walch-Soli-
mena et al., 1997). Taken together, these data indicate that
Smy1p, Myo2p, Sec2p, and Sec4p are involved in event(s)
that affect vesicle delivery and/or capture. Since the myo2
mutation is also synthetically lethal with most of the exo-
cyst mutations, it may be sufficiently detrimental that it
also affects subsequent events. We should point out that
although the most obvious way for Myo2p to play a role is
to be a secretory vesicle motor, there are a number of
other possibilities (refer to Introduction).
In summary, Smy1p does not use microtubule-based
motor activity to compensate for the mutant Myo2p defect.
Regardless of whether or not it is capable of such an activity,
Smy1p must function in some novel manner in its interaction
with Myo2p. The family of actin-related proteins (Mullins
et al., 1996) provides a precedent for proteins with structural
similarity but divergent function; Smy1p may represent an
example of such divergence in the kinesin superfamily.
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